Influenza
Conditions
Keywords
vaccine, safety, intranasal administration
Brief summary
This study evaluates the safety of freeze-dried live attenuated influenza vaccine for intranasal administration in chinese adults aged 3 years and older.80 subjects will be divided into 2 groups, including 18 years and older and 3-17 years old. Subjects in each groups will randomly receive one dose of influenza vaccine or placebo in a 3:1 ratio.
Interventions
BIOLOGICALone dose of Influenza Vaccine
BIOLOGICALplacebo
Sponsors
Beijing Chaoyang District Centre for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects more than 3 years 2. Guardian and/or subjects aged at least 10 subjects can be informed consent, and sign a written Informed Consent Form. 3. Subjects, Guardians and his family can obey the demands of the scheme . 4. Axillary temperature less than 37℃
Exclusion criteria
1. Subjects with flu or infected with flu within 3 months. 2. Subjects have a vaccine allergies, allergic to any kind of composition in experimental vaccine, such as eggs, ovalbumin etc. 3. Subjects have serious side effects to vaccine, such as allergy, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain. 4. Subjects have symptoms of acute infection within a week. 5. Subjects have autoimmune disease or immune function defect, Subjects have used immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past 6 months. 6. Subjects have congenital malformations, developmental disorder or serious chronic diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system disease) 7. Subjects have asthma unstable that need emergency treatment, hospitalization, intubation, oral or intravenous corticosteroid in the past 2 years. 8. Subjects have medical history or family history of convulsions, seizures, encephalopathy and psychiatric disease. 9. Alienia, functional asplenia, and alienia or splenectomy in any situation. 10. Serious neurological disorders such as Green Barry syndrome. 11. Subjects have received blood products or immunoglobulin products within 3 months before experimental vaccine inoculated. 12. Subjects have received other study drug in the past month or received live vaccine, subunit vaccine or inactivated vaccine. 13. The indicators of blood test or urine test do not conform to the inclusion criteria. 14. Subjects have received allergy treatment in in the past 14 days. 15. Subjects are receiving anti-tuberculosis treatment. 16. Subjects have inoculated flu vaccine in the flu reason. 17. Axillary temperature is more than 37℃ before vaccination. 18. Subjects are pregnant or plan to become pregnant 19. Subjects are participate in other clinical trials. 20. Any factors unsuitable for clinical trail at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the rate of adverse reactions of Live Attenuated Influenza Vaccine for Intranasal Administration | 3 months | Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy |
Outcome results
None listed